Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.

Hay J, Gilroy K, Huser C, Kilbey A, Mcdonald A, MacCallum A, Holroyd A, Cameron E, Neil JC.

J Cell Biochem. 2019 Oct;120(10):18332-18345. doi: 10.1002/jcb.29143. Epub 2019 Jun 30.

2.

RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.

Anderson G, Mackay N, Gilroy K, Hay J, Borland G, McDonald A, Bell M, Hassanudin SA, Cameron E, Neil JC, Kilbey A.

J Cell Biochem. 2018 Mar;119(3):2750-2762. doi: 10.1002/jcb.26443. Epub 2017 Nov 20.

3.

RUNX oncoproteins and miRNA networks.

Neil JC, Hay J, Borland G.

Oncotarget. 2017 Sep 7;8(38):62818-62819. doi: 10.18632/oncotarget.20673. eCollection 2017 Sep 8. No abstract available.

4.

The RUNX Genes as Conditional Oncogenes: Insights from Retroviral Targeting and Mouse Models.

Neil JC, Gilroy K, Borland G, Hay J, Terry A, Kilbey A.

Adv Exp Med Biol. 2017;962:247-264. doi: 10.1007/978-981-10-3233-2_16. Review.

PMID:
28299662
5.

Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis.

Terry A, Kilbey A, Naseer A, Levy LS, Ahmad S, Watts C, Mackay N, Cameron E, Wilson S, Neil JC.

J Virol. 2017 Feb 14;91(5). pii: e02119-16. doi: 10.1128/JVI.02119-16. Print 2017 Mar 1.

6.

Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.

Kilbey A, Terry A, Wotton S, Borland G, Zhang Q, Mackay N, McDonald A, Bell M, Wakelam MJ, Cameron ER, Neil JC.

J Cell Biochem. 2017 Jun;118(6):1432-1441. doi: 10.1002/jcb.25802. Epub 2017 Jan 10.

7.

Addiction to RUNX in lymphoma.

Neil JC, Borland G, Kilbey A.

Aging (Albany NY). 2016 Sep 28;8(9):1832-1833. doi: 10.18632/aging.101071. No abstract available.

8.

Gamma-Retrovirus Integration Marks Cell Type-Specific Cancer Genes: A Novel Profiling Tool in Cancer Genomics.

Gilroy KL, Terry A, Naseer A, de Ridder J, Allahyar A, Wang W, Carpenter E, Mason A, Wong GK, Cameron ER, Kilbey A, Neil JC.

PLoS One. 2016 Apr 20;11(4):e0154070. doi: 10.1371/journal.pone.0154070. eCollection 2016.

9.

Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.

Borland G, Kilbey A, Hay J, Gilroy K, Terry A, Mackay N, Bell M, McDonald A, Mills K, Cameron E, Neil JC.

Oncotarget. 2016 Apr 26;7(17):22973-87. doi: 10.18632/oncotarget.8554.

10.

Runx2 contributes to the regenerative potential of the mammary epithelium.

Ferrari N, Riggio AI, Mason S, McDonald L, King A, Higgins T, Rosewell I, Neil JC, Smalley MJ, Sansom OJ, Morris J, Cameron ER, Blyth K.

Sci Rep. 2015 Oct 22;5:15658. doi: 10.1038/srep15658.

11.

In memoriam--Richard M. Elliott (1954-2015).

Brennan B, Weber F, Kormelink R, Schnettler E, Bouloy M, Failloux AB, Weaver SC, Fazakerley JK, Fragkoudis R, Harris M, Barr JN, Palese P, García-Sastre A, Dalziel RG, Dutia BM, Lowen AC, Steel J, Randall RE, Paul Duprex W, Rice CM, Tesh RB, Murphy FA, Ebihara H, Vasconcelos PF, Nunes MR, Fooks AR, Smith GL, Goodfellow I, Pappu HR, Lamb RA, Paterson RG, Higgs S, Vanlandingham DL, Dietzgen RG, Stephen Lodmell J, Nichol ST, Daly J, Ullman DE, Plyusnin A, Plyusnina A, Efstathiou S, Hewson R, Tordo N, Cherry S, Boutell C, Hosie MJ, Murcia PR, Neil JC, Palmarini M, Patel AH, Willett BJ, Kohl A, McLauchlan J.

J Gen Virol. 2015 Aug;96(8):1975-8. doi: 10.1099/jgv.0.000241. No abstract available.

12.

Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo.

Naseer A, Terry A, Gilroy K, Kilbey A, Watts C, Mackay N, Bell M, Mason S, Blyth K, Cameron E, Neil JC.

Viruses. 2015 Apr 17;7(4):2014-29. doi: 10.3390/v7042014.

13.

RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland.

McDonald L, Ferrari N, Terry A, Bell M, Mohammed ZM, Orange C, Jenkins A, Muller WJ, Gusterson BA, Neil JC, Edwards J, Morris JS, Cameron ER, Blyth K.

Dis Model Mech. 2014 May;7(5):525-34. doi: 10.1242/dmm.015040. Epub 2014 Mar 13.

14.

Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis.

Huser CA, Gilroy KL, de Ridder J, Kilbey A, Borland G, Mackay N, Jenkins A, Bell M, Herzyk P, van der Weyden L, Adams DJ, Rust AG, Cameron E, Neil JC.

PLoS Genet. 2014 Feb 27;10(2):e1004167. doi: 10.1371/journal.pgen.1004167. eCollection 2014 Feb.

15.

Biological basis of sex differences in psychopharmacology. Preface.

Neil JC, Kulkarni J.

Curr Top Behav Neurosci. 2011;8:v-vii. No abstract available.

PMID:
21898928
16.

Genome-wide screening in human growth plates during puberty in one patient suggests a role for RUNX2 in epiphyseal maturation.

Emons J, Dutilh BE, Decker E, Pirzer H, Sticht C, Gretz N, Rappold G, Cameron ER, Neil JC, Stein GS, van Wijnen AJ, Wit JM, Post JN, Karperien M.

J Endocrinol. 2011 May;209(2):245-54. doi: 10.1530/JOE-10-0219. Epub 2011 Feb 9.

17.

Runx regulation of sphingolipid metabolism and survival signaling.

Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelam MJ, Cameron ER, Neil JC.

Cancer Res. 2010 Jul 15;70(14):5860-9. doi: 10.1158/0008-5472.CAN-10-0726. Epub 2010 Jun 29.

18.

ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1.

Krapf G, Kaindl U, Kilbey A, Fuka G, Inthal A, Joas R, Mann G, Neil JC, Haas OA, Panzer-Grümayer ER.

Oncogene. 2010 Jun 3;29(22):3307-12. doi: 10.1038/onc.2010.53. Epub 2010 Mar 1.

19.

RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.

Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, Peters G, Stocking C, Cameron E, Neil JC.

Oncogene. 2009 Jul 9;28(27):2502-12. doi: 10.1038/onc.2009.101. Epub 2009 May 18.

20.

A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.

Scobie L, Hector RD, Grant L, Bell M, Nielsen AA, Meikle S, Philbey A, Thrasher AJ, Cameron ER, Blyth K, Neil JC.

Mol Ther. 2009 Jun;17(6):1031-8. doi: 10.1038/mt.2009.59. Epub 2009 Mar 31. Erratum in: Mol Ther. 2009 Aug;17(8):1483. Philbey, Adrain [corrected to Philbey, Adrian]; Thrasher, Adrain J [corrected to Thrasher, Adrian J].

21.

Runx1 promotes B-cell survival and lymphoma development.

Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, Neil JC, Cameron ER.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):12-9. doi: 10.1016/j.bcmd.2009.01.013. Epub 2009 Mar 9.

PMID:
19269865
22.

Oncogene-induced senescence: an essential role for Runx.

Kilbey A, Terry A, Cameron ER, Neil JC.

Cell Cycle. 2008 Aug;7(15):2333-40. Epub 2008 May 29. Review. No abstract available.

23.

Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival.

Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E, Neil JC.

Oncogene. 2008 Oct 2;27(44):5856-66. doi: 10.1038/onc.2008.195. Epub 2008 Jun 16.

24.

Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts.

Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC.

Cancer Res. 2007 Dec 1;67(23):11263-71.

25.

Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas.

Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC.

Cancer Res. 2007 Jun 1;67(11):5126-33.

26.

Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.

Dunham SP, Bruce J, Klein D, Flynn JN, Golder MC, MacDonald S, Jarrett O, Neil JC.

Vaccine. 2006 Nov 30;24(49-50):7095-108. Epub 2006 Jul 18.

PMID:
17049683
27.

Limited efficacy of an inactivated feline immunodeficiency virus vaccine.

Dunham SP, Bruce J, MacKay S, Golder M, Jarrett O, Neil JC.

Vet Rec. 2006 Apr 22;158(16):561-2. No abstract available.

PMID:
16632531
28.

Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.

Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER.

Cancer Res. 2006 Feb 15;66(4):2195-201.

29.

The RUNX genes: gain or loss of function in cancer.

Blyth K, Cameron ER, Neil JC.

Nat Rev Cancer. 2005 May;5(5):376-87. Review.

PMID:
15864279
30.

Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Hosie MJ, Klein D, Binley JM, Dunsford TH, Jarrett O, Neil JC, Knapp E, Giannecchini S, Matteucci D, Bendinelli M, Hoxie JA, Willett BJ.

J Virol. 2005 Feb;79(3):1954-7.

31.

Conservation and expression of an alternative 3' exon of Runx2 encoding a novel proline-rich C-terminal domain.

Terry A, Kilbey A, Vaillant F, Stewart M, Jenkins A, Cameron E, Neil JC.

Gene. 2004 Jul 7;336(1):115-25.

PMID:
15225881
32.

The Runx genes: lineage-specific oncogenes and tumor suppressors.

Cameron ER, Neil JC.

Oncogene. 2004 May 24;23(24):4308-14. Review.

PMID:
15156187
33.

Nomenclature for Runt-related (RUNX) proteins.

van Wijnen AJ, Stein GS, Gergen JP, Groner Y, Hiebert SW, Ito Y, Liu P, Neil JC, Ohki M, Speck N.

Oncogene. 2004 May 24;23(24):4209-10. No abstract available.

PMID:
15156174
34.

RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53.

Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, Friedman AD, Baxter EW, Neil JC, Cameron ER.

Oncogene. 2004 Jul 15;23(32):5476-86.

PMID:
15133495
35.

Mutations in the candidate tumour suppressor gene FLJ12973 on chromosome 15q15 are rare in colorectal cancer.

Fleischmann C, Bevan S, Neil JC, Terry A, Houlston RS.

Cancer Lett. 2003 Jun 30;196(1):65-7.

PMID:
12860291
36.

The Runx genes as dominant oncogenes.

Cameron ER, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S, Neil JC.

Blood Cells Mol Dis. 2003 Mar-Apr;30(2):194-200. Review.

PMID:
12732183
37.

Long-range effects of retroviral insertion on c-myb: overexpression may be obscured by silencing during tumor growth in vitro.

Hanlon L, Barr NI, Blyth K, Stewart M, Haviernik P, Wolff L, Weston K, Cameron ER, Neil JC.

J Virol. 2003 Jan;77(2):1059-68.

38.

Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.

Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, Cameron ER.

Cancer Res. 2002 Dec 15;62(24):7181-5.

39.

Feline immunodeficiency virus integration in B-cell lymphoma identifies a candidate tumor suppressor gene on human chromosome 15q15.

Beatty J, Terry A, MacDonald J, Gault E, Cevario S, O'Brien SJ, Cameron E, Neil JC.

Cancer Res. 2002 Dec 15;62(24):7175-80.

40.

Retroviral insertion sites and cancer: fountain of all knowledge?

Neil JC, Cameron ER.

Cancer Cell. 2002 Oct;2(4):253-5. Review.

41.

Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection.

Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER.

J Immunol. 2002 Sep 15;169(6):2866-74.

42.

Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.

Hosie MJ, Willett BJ, Klein D, Dunsford TH, Cannon C, Shimojima M, Neil JC, Jarrett O.

J Virol. 2002 Jun;76(12):6062-72.

43.
44.

Linkage on chromosome 10 of several murine retroviral integration loci associated with leukaemia.

Haviernik P, Festin SM, Opavsky R, Koller RP, Barr NI, Neil JC, Wolff L.

J Gen Virol. 2002 Apr;83(Pt 4):819-27.

PMID:
11907331
45.

Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18.

Dunham SP, Flynn JN, Rigby MA, Macdonald J, Bruce J, Cannon C, Golder MC, Hanlon L, Harbour DA, Mackay NA, Spibey N, Jarrett O, Neil JC.

Vaccine. 2002 Feb 22;20(11-12):1483-96.

PMID:
11858854
47.

Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, McDonald M, McGillivray C, Jarrett O, Neil JC, Onions DE.

J Virol. 2001 Sep;75(18):8424-33.

48.

Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.

Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M.

Oncogene. 2001 Jan 18;20(3):295-302.

49.

Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Hosie MJ, Dunsford T, Klein D, Willett BJ, Cannon C, Osborne R, Macdonald J, Spibey N, Mackay N, Jarrett O, Neil JC.

J Virol. 2000 Oct;74(20):9403-11.

50.

Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene.

Drissi H, Luc Q, Shakoori R, Chuva De Sousa Lopes S, Choi JY, Terry A, Hu M, Jones S, Neil JC, Lian JB, Stein JL, Van Wijnen AJ, Stein GS.

J Cell Physiol. 2000 Sep;184(3):341-50.

PMID:
10911365

Supplemental Content

Support Center